Transforming genetic discoveries into groundbreaking treatments
We are accelerating the journey from genetic discovery to groundbreaking therapies in neurology, autoimmune diseases, and inflammatory skin conditions.
Our R&D efforts are operated by a team of international experts in genomics, bioinformatics, neurology, inflammation and immunology
– augmented by a world-class network of leading scientists and research institutions across the United States and Europe.
The Pulse
-
REYKJAVIK, ICELAND – February 11, 2026 – Arctic Therapeutics (ATx) today announced that the first patients have been enrolled in a Phase IIa randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of topical AT-004 in patients with acne vulgaris (AV). The study follows regulatory approval from the European Medicines…
Events
23 February
Drug R&D 202626 February
Pharma Synergy Partnering Meeting02 March
BIO Investment & Growth Summit